Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DapaBalci-Leap
2024-516032-10-00Phase 2Completed
- Sponsor
- Winicker Norimed
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of dapagliflozin and balcinrenone in chronic kidney disease (CKD) (4 arms), sponsored by Winicker Norimed. Primary endpoint: Change from baseline in 24h urine glucose excretion at day 3 and day 28. Started Aug 2024; status: completed.
02
Drugs
dapagliflozinbalcinrenone
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2024-516032-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516032-10-00.